Inspra

Eplerenone, the active ingredient in Inspra, is an aldosterone antagonist presented as an oral tablet for oral use. It is employed to manage high blood pressure, reduce the risk of cardiovascular events in patients with reduced‑ejection‑fraction heart failure, and improve outcomes after a myocardial infarction.

GNH USA supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable global distribution.

Eplerenone acts on the mineralocorticoid pathway to treat several cardiovascular conditions.

Hypertension: lowers blood pressure by reducing sodium and water retention. Heart failure with reduced ejection fraction: improves survival and reduces hospitalizations by decreasing cardiac remodeling. Post‑myocardial infarction: lowers the risk of cardiovascular death and heart failure when added to standard therapy.

Eplerenone may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Nausea - Diarrhoea - Abdominal pain

Serious or Rare Side Effects: - Hyperkalaemia - Acute renal impairment - Severe allergic reactions (including angio‑edema) - Hepatic dysfunction - Gynecomastia - Life‑threatening arrhythmias

Before initiating therapy, clinicians should assess individual risk factors and monitor laboratory parameters.

Monitor potassium levels: regular blood tests are required to detect hyperkalaemia. Assess renal function: adjust use in patients with impaired kidney function. Avoid use with potassium‑sparing diuretics: increased risk of high potassium. Caution in elderly: increased sensitivity to blood pressure changes. Pregnancy and lactation: safety not established; use only if benefits outweigh risks. Store at ambient temperature: keep in original container, protect from moisture and heat.

Eplerenone interacts with several drug classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalaemia. - ACE inhibitors or ARBs: combined use can increase potassium and renal risk. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): raise eplerenone levels.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce renal clearance and increase potassium. - Digoxin: monitor for toxicity due to altered electrolyte balance. - Lithium: monitor serum levels as potassium changes affect lithium clearance.